Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | SDHB | P21912 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305422 | 1.00 | MAPT (0.35) | MAPTTP53LMNASMN1; SMN2CSNK1D | |
| SCHEMBL30305463 | 0.84 | TNIK (0.39) | MAPTTGFBR1MAPK14 | |
| SCHEMBL23985120 | 0.84 | TNIK (0.39) | MAPTTGFBR1MAPK14 | |
| SCHEMBL30855988 | 0.83 | AKR1C3 (0.37) | MAPTTP53LMNAADCY8ADCY1 | |
| SCHEMBL31620327 | 0.83 | AKR1C3 (0.37) | MAPTTP53LMNAADCY8ADCY1 | |
| SCHEMBL23985115 | 0.82 | JAK2 (0.39) | MAPTTGFBR1MAPK14 | |
| SCHEMBL30305529 | 0.82 | JAK2 (0.39) | MAPTTGFBR1MAPK14 | |
| SCHEMBL23985113 | 0.81 | KDR (0.35) | CSNK1DCSNK1ETGFBR1MAPK14 | |
| SCHEMBL30305520 | 0.81 | KDR (0.35) | CSNK1DCSNK1ETGFBR1MAPK14 | |
| SCHEMBL23985112 | 0.81 | TGFBR1 (0.37) | LMNATGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | RELAY THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | PIK3CD, PIK3CB, PIK3R1 | MAPT 3123/4885TP53 527/4885LMNA 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.